entertainment -WSS

entertainment

author：comprehensive 2025-09-14 10:01:34 - browse：578

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Eli Lilly reports tirzepatide MASH success during Q4 earnings

hotspot

WSS

Congress considering partial increase for doctor pay in Medicare

Long Covid research funding gets a major boost from NIH

Congress must protect the remaining independent doctors

Congress must protect the remaining independent doctors

Pennsylvania man bitten on the head by bear during attack in his garage

Ebola vaccine can save some who are already sick, per new study

hotspot

entertainment

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AMAs digital advisors table RPM coding reform proposal, again

As demand for Covid shots wanes, Moderna seeks its next success

Kansas bar where gunfire wounded 9 last month closes permanently

Moonlake's readout produced a cash windfall. Risks remain

Tome Biosciences co

Hepatitis C has a cure — but many Americans still lack access to it

Sage considers ways to reduce costs following FDA rejection

Guidelines to prevent youth baseball injuries need more muscle

Why don't Americans have at

hotspot

Juul documents reveal insider tactics on political lobbying

Abbott's new heart device gets FDA advisory panel nod

Doctors on social media are being harassed and cyberbullied

Sage considers ways to reduce costs following FDA rejection

Trump used to be more articulate. What could explain the change?

Flash flood warnings continue for parts of Missouri, Illinois

hotspot

hotspot

focus

Wikipedia